Takeda & MSD to End Co-promotion Deal for Daxas

Takeda will use its own sales organization to market the once-daily tablet for patients with chronic obstructive pulmonary disease.

Takeda Pharmaceuticals International GmbH has reached a mutual agreement with Merck & Co., Inc. (based in Whitehouse Station, New Jersey and known as MSD outside the USA and Canada) to terminate their co-promotion agreement for Daxas? (roflumilast) in certain European countries and Canada as of December 31, 2011.

MSD will return the rights to Daxas? to Takeda in all countries covered by the agreement.

As a result of the significant strengthening of the combined organization following Nycomed’s acquisition by Takeda Pharmaceutical Company Limited (“Takeda”) at the end of Septembe